Company Overview of Adamas Pharmaceuticals, Inc.
Key Executives for Adamas Pharmaceuticals, Inc.
|Gregory T. Went Ph.D.||27 Relationships||Chairman and Chief Executive Officer||51|
|William J. Dawson||6 Relationships||Chief Financial Officer||60|
|Natalie L. McClure Ph.D.||No Relationships||Senior Vice President of Product Development||62|
|Rajiv Patni M.D.||No Relationships||Chief Medical Officer||46|
Adamas Pharmaceuticals, Inc. Board Members*
|Name||Board Relationships||Primary Company||Age|
|Gregory T. Went Ph.D.||27 Relationships||Adamas Pharmaceuticals, Inc.||51|
|David L. Mahoney||42 Relationships||Adamas Pharmaceuticals, Inc.||61|
|Richard H. Booth CPA, CLU, ChFC||66 Relationships||1347 Capital Corp.||68|
|Martha J. Demski||37 Relationships||Ajinomoto Althea, Inc.||62|
|William W. Ericson J.D.||156 Relationships||Wildcat Venture Partners||56|
Adamas Pharmaceuticals, Inc. Executive Committees*
|Committee Name||Chairperson||Board Relationships||Members|
|Audit Committee||Martha J. Demski||37 Relationships||3 Executives|
|Compensation Committee CPA, CLU, ChFC||Richard H. Booth||66 Relationships||2 Executives|
|Nominating Committee||David L. Mahoney||42 Relationships||3 Executives|
|Corporate Governance Committee||David L. Mahoney||42 Relationships||3 Executives|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
CEO COMPENSATION IN THIS INDUSTRY
|Total Short Term Compensation|
|Total Value of Options||$770.0K|
INDUSTRY EXECUTIVE CHANGES
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.